Over 20 years 42 of 138 patients with systemic lupus erythematosus "died"-that is, suffered actual death or went into terminal renal failure, or both; data from 41 were available for analysis. In most patients the causes of death were multiple. Twenty seven patients went into terminal renal failure, of whom 25 were offered dialysis treatment. Three regained renal function later, 12 survived on dialysis or with functioning kidney allografts-almost ali with inactive lupus-but 13 died after starting dialysis, most within a few weeks or months. The principal causes were active lupus or infection. In those patients with renal failure after rapid deterioration in renal function (n=14) there were nine deaths, while of 10 patients with a slow evolution into renal failure, only four died.
Introduction
There is considerable information on causes of death in systemic lupus erythematosus. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Even in series reporting the whole range of lupus, with or without evident renal disease, renal failure emerges as an important cause of death. Equally, patients with lupus nephritis may fall victim to other manifestations of lupus, to complications of treatment, or to associated features such as vascular disease. The problem has been complicated further by the availability of substitution therapy for renal failure in the form of dialysis and trans-plantation. Patients surviving renal failure oflupus nephritis remain at risk from fatal disease in other organs caused by the lupus. Thus even though we have data on causes of death in lupus, many of these data do not apply to patients with nephritis as the principal clinical feature, and the impact of substitution therapy has been taken into account in very few series.
The fate of patients requiring renal replacement therapy because of lupus nephritis has been described,'"2 and we have detailed our own experience elsewhere." The purpose of this paper is to examine the overall pattern of mortality in our patients suffering from lupus, all of whom had prominent renal disease, in order to assess the relative roles of extrarenal lupus and complications of treatment in determining mortality when compared with renal failure itself.
Patients and methods
Between 1964 and 1982, 138 patients with systemic lupus erythematosus were referred to the renal unit at Guy's Hospital. All satisfied the preliminary (1971) and 1982 criteria of the American Rheumatism Association23 and all had on at least one occasion (usually many) a positive antinuclear factor preparation or a raised binding capacity for double stranded DNA, or both, in serum. All had clinical evidence of nephritis, with proteinuria or abnormalities of the urinary sediment, and all had undergone renal biopsy at some time yielding histological evidence of lupus nephritis. After assessment and planning of treatment some of the patients returned to the care of the referring centre, but most were followed up in the renal unit, either solely or jointly with the referring physician.
During follow up, varying from two to 22 years (mean 8 4 years), 42 of the patients (30 4%) either died or entered end stage renal failure, events which together are referred to as "death" (since patients reaching end stage renal failure would have died but for substitution therapy, so that the patients who in fact survived by virtue of dialysis or transplantation were for actuarial analysis regarded as dead). One patient was excluded from the study because there was insufficient information on her death, which occurred elsewhere.
CAUSES OF DEATH
Since in nearly all cases death resulted from several factors, we did not attempt to ascribe a single main cause for each patient. Instead we classified the causes of death under six headings.
Active generalised lupus was defined as progressive spread of the disease to several systems, causing severe dysfunction with immunological or histological evidence of disease activity.
Active lupus, single organ was defined as progressive spread of the disease to affect one major organ, causing severe dysfunction without evidence or with only minor disruption of other systems, with immunological or histological evidence of disease activity.
Inactive lupus was defined as evidence of previous organ damage causing dysfunction but with no signs of continuing clinical or immunological activity at the time of death.
Vascular was defined as clinical or histological evidence of major life threatening occlusion of coronary, cerebral, or peripheral circulation.
Infection was defined as major infection(s) which contributed to or caused the death of the patient.
Other, unrelated was defined as other causes of death not related to systemic lupus erythematosus or its treatment.
Disease of the kidney caused by systemic lupus erythematosus presents a 
ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS BEFORE AND AT DEATH
In analysing the activity of systemic lupus erythematosus before and at entry into end stage renal failure renal damage by systemic lupus erythematosus was considered similarly to active lupus affecting other organs.
Clinically "active" lupus nephritis was recorded as present if there was (a) proteinuria or active urinary sediment with (b) extrarenal manifestations of lupus activity, even if minor and not life threatening, such as skin or joint disease, together with (c) immunological or histological evidence of activity.
Histological appearances of renal biopsy or necropsy specimens were judged to be "active" when fresh cellular crescents, diffuse or focal active proliferation of endocapillary cells, tuft necrosis, capillary thrombosis, or vasculitis was visible.
Immunological evidence of disease activity was defined as low serum concentrations of C3 (<55% normal) and C4 (<50% normal), a raised binding titre of serum deoxyribonucleic acid (>30 [tm), or (when available) the presence of excess amounts of immune complex like material in the serum.
RATE OF DETERIORATION IN RENAL FUNCTION
For analysis the patients were divided into (a) those with rapid deterioration in renal function, defined as a fall in glomerular filtration rate of 40 ml/min or more or a rise in plasma creatinine concentration of 500 [tmol/l (5 7 mg/100 ml) or more in the three months before end stage renal failure, and (b) those with slow deterioration if less than this.
TIMING OF "DEATH"
Patients who suffered true death or went into end stage renal failure were divided into those with early death or renal failure, defined as occurring less than two years after onset of systemic lupus erythematosus, and those with late death, when the interval was greater than this.
STATISTICAL
Analysis of dependency in two way tables was performed using the G test with Yates's correction for small samples.24
Results
There were 36 female and five male patients in the study, with a mean age at death of 35-8 years (range 11-63). Those who went into renal failure but did not die were of almost identical age (mean 35-4 years; range 11-63). Eight were of West Indian origin, two west African, two Arab, two Chinese, one Pakistani, one Iranian, one Greek, and 24 of resident British stock. Tables I and II show the circumstances of "death" of the 41 patients. Twelve patients (cases 1-12; table I) who went into end stage renal failure received renal substitution therapy and survived. Of these, at last follow up four had functioning renal cadavericallografts, six were receiving dialysis, and two (cases 11 and 12) had recovered sufficient renal function to survive without dialysis; one patient (case 10) had a temporary recovery of renal function.
FINDINGS AT AND BEFORE DEATH OR RENAL FAILURE
Fifteen patients (cases 13-27) went into end stage renal failure and subsequently died (table II) . Two (cases 13 and 14) were not offered substitution therapy; one was paraplegic and the other demented. The remaining 13 patients began dialysis. Three patients (cases 24, 26, and 27) died after more than one month of dialysis, and the other 10 died within one month of beginning dialysis, most commonly from active lupus. The remaining 14 patients (cases 28-41; Tables III and IV analyse the causes of the true deaths in detail. In the 10 patients who died shortly after beginning treatment for end stage renal failure (cases 15-23 and 25) the causes of death were mainly active systemic lupus erythematosus and infection. The three patients who died more than one month after beginning treatment did so because of recurring manifestations of lupus in the central nervous system after three months of haemodialysis (case 24), gastrointestinal bleeding during a rejection episode one and a half months after transplantation and an initial month on haemodialysis (case 26), and myocardial infarction five years after transplantation, with good graft function (case 27). Infection was the single commonest cause of death in those with functioning kidneys (table IV) .
ANALYSIS OF DEATHS IN RELATION TO COURSE OF DISEASE
Causes of "death" as classified in tables I-III were analysed in terms of the duration of the disease and the effect on the kidneys (renal versus non-renal deaths). Table V summarises the causes ofdeath in patients dying within two years of onset (early deaths) and those who died later (late deaths). The totals were in both categories greater (56 in all) than the number of patients, since in many the causes were multiple. In the 17 early deaths active systemic lupus erythematosus (12 cases) and infection (eight cases) predominated. In the 24 late deaths, although active systemic lupus erythematosus was still prominent (eight cases), vascular deaths became important (six). Statistical analysis showed that active systemic lupus erythematosus was significantly more common (p<005) in early than in late deaths, but no other differences reached significance. Deaths from renal causes were also commoner in the late group, but this also did not reach significance at the 5% level.
Analysis of the timing of the main categories of "death" after diagnosis (fig) showed that the number of deaths decreased progressively with time. This reflected not only a fall off in the number of patients at risk (fig) but also a real decrease in mortality with time.
Clinical circumstances of entering end stage renal failure were correlated with outcome in patients offered renal substitution therapy. Table VI summarises the activity of systemic lupus erythematosus, renal histology, treatment, and outcome according to the rate of deterioration of renal function in the three months preceding end stage renal failure. One patient (case 9) had to be excluded from this analysis because there were insufficient data to assess the rate of decline in her renal function. The mortality among those with a rapid decline in renal function and active systenmic lupus erythematosus at end stage renal failure (14 patients) was high (64%), whereas those with a slow decline and inactive lupus (10 patients) did better (40% mortality). This difference just failed to reach significance at the 5% level.
FOLLOW UP IN RENAL FAILURE
The 15 patients who survived the period immediately after end stage renal failure were followed up for a total of 36 patient years (mean 2 4 years; range 2-5 months to 5-0 years). Ten patients were dialysed for more than three consecutive months for a total of 233 patient months (mean 23 months; range 3-5 to 58 months).
Persistent or recurring active extrarenal systemic lupus erythematosus was not a major problem in patients surviving end stage renal failure. Of the six patients who had active disease before starting dialysis, only one died (elsewhere) from recurrent manifestations of lupus in the central nervous system and three patients had exacerbations (cutaneous and minor neurological), easily controlled by a temporary increase in immunosuppression and mainly during the first year of dialysis. Only one of the patients who had inactive lupus at end stage renal failure later had recurrent activity (case 1: episode of arthritis with depressed complement values and raised DNA binding titre after two years of haemodialysis). All patients receiving dialysis were maintained with small doses of prednisone (5-15 mg/24 h) and azathioprine (1-2 mglkgl24 h). Three patients were able to discontinue dialysis (cases 10 to 12), although in one 'case 10) dialysis was reinstituted after 32 months and another (case I 1) again went into terminal uraemia. 
Conclusions and discussion
A principal finding in this study was of a group of patients (10 out of the total of 25) who died very soon despite beginning dialysis. 22 With two exceptions they reached terminal renal failure after a phase of rapidly declining renal function. In most this seemed to be due to active lupus nephritis, although other haemodynamic factors may have contributed to the rapid deterioration in glomerular filtration rate.
The patients who survived the period immediately after end stage renal failure fared relatively well, and the few who had active lupus at that stage experienced progressively fewer extrarenal manifestations while receiving low doses of corticosteroids and azathioprine as maintenance treatment. The rare "flares" of active disease were easily controlled. There were three deaths in this group, but only one was due to a recrudescence of lupus, again shortly after end stage renal failure. large multicentre study, Rosner et al found vascular events to be an infrequent cause of death'6 (only six patients died from myocardial infarction and another six from cerebrovascular accident out of a total of 22 deaths); but in other series myocardial infarction was reportedly much more commonly responsible for the death of patients suffering from systemic lupus erythematous.9 " 3"42 We found that vascular events were a relatively uncommon but none the less important cause of death (7 out of 41 patients). The finding of six young women patients (all under 40) with severe ischaemic heart disease is striking and raises the possibility that obvious or unidentified atherogenic factors may be responsible for the particularly advanced disease in a subgroup of patients.
Vascular disease in systemic lupus erythematosus has been attributed variously to corticosteroids,4' hypertension, and the persistence of nephrotic hyperlipidaemia,43 chronic renal failure, or the disease itself. The most interesting possibility, however, is that in some way the immunological events ofsystemic lupus erythematosus -and in particular the abundant circulating immune complexesinteract with other risk factors for cardiovascular disease which may be present to increase the risk of disease events to high levels. 6 42 The presence of circulating immune complexes is known to potentiate the effect of a high lipid diet in rabbits4 and baboons4" and the restriction of fat in the diet' or the feeding of eicosapentaenoic acid4/ to protect NZBAW mice from vascular lesions, in the latter case also prolonging life by ameliorating the renal disease. By contrast, feeding a high fat diet accelerates the glomerular disease.' In these mice as well as those of the MRL/1 and B xSB strains myocardial infarction is a common event, affecting 25-30% ofmice. 49 In the important study of Haider and Roberts the degree of postmortem narrowing of the coronary arteries in patients dying of systemic lupus erythematosus under the age of 40 was compared with age and sex matched controls.42 Advanced lesions were present in half the patients, the remainder showing narrowing comparable to that in the control group. In these two subgroups those with coronary narrowing showed higher serum cholesterol concentrations, higher blood pressure, and non-coronary heart lesions such as pericarditis and valve lesions, but the corticosteroid dosage was the same. Pedro Correia was supported by a grant from the Junta Nacional de Investigacao Cientifica Technologica (JNICT).
Addendum
After this paper was written a further patient, a girl aged only 12, died of a myocardial infarct proved at necropsy just after starting regular dialysis. She had had lupus for only 18 months and the condition appeared to be an acute vasculitis rather than degenerative disease. Ishikawa et al also described myocardial infarction in a child with lupus, from diffuse atherosclerosis only two years from onset of lupus.51
